X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2018 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Unichem Lab with Panacea Biotech - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

UNICHEM LAB vs PANACEA BIOTECH - Comparison Results

PANACEA BIOTECH 
   Change

Panacea Biotec is the second largest vaccine producer in India and has been ranked as the third largest biotechnology company in India (as per ABLE Survey 2006). While vaccines account for two-thirds of the company's overall revenues, the balance com... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    UNICHEM LAB PANACEA BIOTECH UNICHEM LAB/
PANACEA BIOTECH
 
P/E (TTM) x -64.1 -21.1 - View Chart
P/BV x 0.7 2.5 28.7% View Chart
Dividend Yield % 2.4 0.0 -  

Financials

 UNICHEM LAB   PANACEA BIOTECH
EQUITY SHARE DATA
    UNICHEM LAB
Mar-18
PANACEA BIOTECH
Mar-14
UNICHEM LAB/
PANACEA BIOTECH
5-Yr Chart
Click to enlarge
High Rs382149 256.9%   
Low Rs23482 284.4%   
Sales per share (Unadj.) Rs116.384.1 138.2%  
Earnings per share (Unadj.) Rs-18.9-18.3 103.4%  
Cash flow per share (Unadj.) Rs-11.7-6.7 175.3%  
Dividends per share (Unadj.) Rs5.000-  
Dividend yield (eoy) %1.60-  
Book value per share (Unadj.) Rs381.083.7 455.2%  
Shares outstanding (eoy) m70.3461.25 114.8%   
Bonus/Rights/Conversions BB--  
Price / Sales ratio x2.61.4 193.0%   
Avg P/E ratio x-16.3-6.3 258.1%  
P/CF ratio (eoy) x-26.2-17.2 152.2%  
Price / Book Value ratio x0.81.4 58.6%  
Dividend payout %-26.40-   
Avg Mkt Cap Rs m21,6687,074 306.3%   
No. of employees `0002.32.8 82.9%   
Total wages/salary Rs m2,0061,449 138.4%   
Avg. sales/employee Rs Th3,587.81,874.1 191.4%   
Avg. wages/employee Rs Th880.0527.0 167.0%   
Avg. net profit/employee Rs Th-583.7-407.7 143.2%   
INCOME DATA
Net Sales Rs m8,1805,154 158.7%  
Other income Rs m610100 611.3%   
Total revenues Rs m8,7905,254 167.3%   
Gross profit Rs m-1,320-766 172.3%  
Depreciation Rs m505711 71.0%   
Interest Rs m801,503 5.3%   
Profit before tax Rs m-1,295-2,881 45.0%   
Minority Interest Rs m011 0.0%   
Prior Period Items Rs m-2-6 38.6%   
Extraordinary Inc (Exp) Rs m01,771 0.0%   
Tax Rs m3317 198.9%   
Profit after tax Rs m-1,331-1,121 118.7%  
Gross profit margin %-16.1-14.9 108.5%  
Effective tax rate %-2.6-0.6 442.4%   
Net profit margin %-16.3-21.8 74.8%  
BALANCE SHEET DATA
Current assets Rs m23,3183,810 612.0%   
Current liabilities Rs m4,6358,365 55.4%   
Net working cap to sales %228.4-88.4 -258.4%  
Current ratio x5.00.5 1,104.5%  
Inventory Days Days122156 78.2%  
Debtors Days Days12167 180.7%  
Net fixed assets Rs m8,16314,480 56.4%   
Share capital Rs m14161 229.5%   
"Free" reserves Rs m26,660903 2,952.1%   
Net worth Rs m26,8015,127 522.7%   
Long term debt Rs m35,832 0.1%   
Total assets Rs m31,89019,433 164.1%  
Interest coverage x-15.2-0.9 1,655.3%   
Debt to equity ratio x01.1 0.0%  
Sales to assets ratio x0.30.3 96.7%   
Return on assets %-3.92.0 -199.7%  
Return on equity %-5.0-21.9 22.7%  
Return on capital %-4.53.6 -124.9%  
Exports to sales %024.5 0.0%   
Imports to sales %010.2 0.0%   
Exports (fob) Rs mNA1,264 0.0%   
Imports (cif) Rs mNA525 0.0%   
Fx inflow Rs m4,3561,539 283.0%   
Fx outflow Rs m0942 0.0%   
Net fx Rs m4,356597 729.5%   
CASH FLOW
From Operations Rs m-1,123599 -187.5%  
From Investments Rs m16,487-438 -3,764.9%  
From Financial Activity Rs m-8,811-303 2,911.9%  
Net Cashflow Rs m6,552-141 -4,636.9%  

Share Holding

Indian Promoters % 50.1 74.5 67.2%  
Foreign collaborators % 0.0 0.0 -  
Indian inst/Mut Fund % 15.1 0.6 2,516.7%  
FIIs % 3.0 1.3 230.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 31.7 23.6 134.3%  
Shareholders   20,176 10,259 196.7%  
Pledged promoter(s) holding % 0.0 35.1 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare UNICHEM LAB With:   GLENMARK PHARMA  J.B.CHEMICALS  DR. REDDYS LAB  DIVIS LABORATORIES  FULFORD INDIA  

Compare UNICHEM LAB With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Stock Market's Sudden Crash; Rising Oil Prices; Banking Stocks and Top Cues in Action Today(Pre-Open)

The Indian share markets ended lower on Friday. The S&P BSE Sensex partially recovered after crashing 1,000 points in intraday trade to settle 280 points lower.

Related Views on News

UNICHEM LAB Announces Quarterly Results (1QFY19); Net Profit Down 1479.6% (Quarterly Result Update)

Aug 3, 2018 | Updated on Aug 3, 2018

For the quarter ended June 2018, UNICHEM LAB has posted a net profit of Rs 207 m (down 1479.6% YoY). Sales on the other hand came in at Rs 2 bn (down 35.9% YoY). Read on for a complete analysis of UNICHEM LAB's quarterly results.

PANACEA BIOTECH Announces Quarterly Results (4QFY18); Net Profit Down 66.5% (Quarterly Result Update)

Jun 20, 2018 | Updated on Jun 20, 2018

For the quarter ended March 2018, PANACEA BIOTECH has posted a net profit of Rs 86 m (down 66.5% YoY). Sales on the other hand came in at Rs 2 bn (up 0.3% YoY). Read on for a complete analysis of PANACEA BIOTECH's quarterly results.

Aster DM Healthcare (IPO)

Feb 10, 2018

Should you subscribe to the IPO of Aster DM Healthcare Ltd?

Dr Reddy's: Milestone Payment Drives Sales (Quarterly Results Update - Detailed)

Feb 9, 2018

US business was hit by pricing pressure although there was growth sequentially led by new product launches.

Lupin: US market Declines Due to Higher Base Effect of FY17 (Quarterly Results Update - Detailed)

Feb 9, 2018

Price erosion in generic US drugs continues but seems to be bottoming out.

More Views on News

Most Popular

My First Pharma Stock Recommendation!(The 5 Minute Wrapup)

Sep 21, 2018

This company has not only created a niche in the pharma space, it has done so profitably.

Want Bigger Returns Than You Thought Possible? This is Where You Should Look(Profit Hunter)

Sep 12, 2018

Richa has discovered the single most profitable opportunity in the market - read on to discover more...

Are You Blindly Investing In Equities? Read This...(Outside View)

Sep 11, 2018

PersonalFN explains how blindly investing in equities can prove hazardous to your wealth and health.

Investors Are Redeeming From Equity Mutual Funds Now. Should You?(Outside View)

Sep 12, 2018

PersonalFN elucidates if you should redeem from equity mutual fund now, and the approach to follow before you decide to sell mutual funds.

Outperformance of Strong Established Brands in the Indian Stock market(Chart Of The Day)

Sep 14, 2018

Strong Well established Indian Brands have comfortably outperformed the index in the decade post the global financial crisis.

More

Small Investments
BIG Returns

Zero To Millions Guide 2018
Get our special report, Zero To Millions
(2018 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

UNICHEM LAB SHARE PRICE


Sep 21, 2018 (Close)

TRACK UNICHEM LAB

  • Track your investment in UNICHEM LAB with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

UNICHEM LAB - SANOFI INDIA COMPARISON

COMPARE UNICHEM LAB WITH

MARKET STATS